Increased serum concentrations of conjugated diens and malondialdehyde in patients with pulmonary tuberculosis

Citation
S. Kwiatkowska et al., Increased serum concentrations of conjugated diens and malondialdehyde in patients with pulmonary tuberculosis, RESP MED, 93(4), 1999, pp. 272-276
Citations number
32
Categorie Soggetti
Cardiovascular & Respiratory Systems","da verificare
Journal title
RESPIRATORY MEDICINE
ISSN journal
09546111 → ACNP
Volume
93
Issue
4
Year of publication
1999
Pages
272 - 276
Database
ISI
SICI code
0954-6111(199904)93:4<272:ISCOCD>2.0.ZU;2-X
Abstract
During pulmonary inflammation increased amounts of reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI) are produced as a consequen ce of phagocyte respiratory burst. One of the manifestations of these free radical-mediated processes is lipid peroxidation (LP). The aim of our study was to assess the concentration of lipid peroxidation products (LPPs), conjugated diens (CD) and malondialdehyde (MDA), in patien ts with active TB. Forty-two patients were enrolled into the study. Half (group I) had advance d TB and were sputum smear-positive. The remainder (group II) had only smal l radiographical changes and were sputum smear-negative. Serum concentratio ns of CD and MDA were measured at days 0, 7, 14 and 28 in group I and day 0 in group TT. We found that in all patients with active TB C-CD (1.0 +/- 0. 05A(233)) and C-MDA (2.01 +/- 0.16 nmol dl(-1)) were significantly elevated compared to healthy controls (0.67 +/- 0.03A(233) and 1.36 +/- 0.08 nmol d l(-1), respectively) (P<0.001). The highest levels of LPPs were in patients with advanced TB. These concentrations were stable during the first month of anti-tuberculous therapy. Our data indicated that, as in bacterial pneumonia, LPPs were enhanced in a ctive TB. The levels of LPPs depended on the form of the disease as they we re higher in subjects with advanced disease than in those with only small r adiographical changes. Further studies are needed to assess the role of ant ioxidants as adjuvant therapy in patients with pulmonary TB.